Acadian Asset Management
EIDX

Acadian Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Acadian Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,149
Closed -$55K – 2452
2020
Q2 		$55K Buy
+1,149
New +$53.4K ﹤0.01% 1892
2020
Q1 		– Sell
-1,639
Closed -$94K – 2012
2019
Q4 		$94K Buy
+1,639
New +$81.2K ﹤0.01% 1479

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Acadian Asset Management's EIDX Position: Q3 2020 in Review

Acadian Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2020, closing a stake of 1,149 shares — an estimated $55K sold.

Acadian Asset Management first reported a position in EIDX in Q4 2019 and held it in 2 quarters. The position peaked at $94K in Q4 2019. 91 funds tracked by Wall St. Rank hold EIDX as of Q3 2020.

  • Acadian Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Acadian Asset Management sold 1,149 Eidos Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $55K.
  • Acadian Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Acadian Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $94K in Q4 2019.
  • 91 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Acadian Asset Management's 13F filing for Q3 2020, filed 9 Nov 2020.